** Brokerage J.P.Morgan upgrades medical product maker Bioventus to "neutral" from "underweight", raises PT to $13 from $12
** Notes better visibility into co's growth; says co has taken steps in the right direction to stabilize and restore growth
** Says 2024 marked return to stability for co, with knee-therapy-related headwinds now lapped and fully in rearview and "pockets of strength" in areas including Ultrasonics
** Expects deals, while likely off the table for co in near to midterm future, could get investors confident in driving upside to numbers
** Says M&A has historically been a key factor in co's growth algorithm given its limited organic pipeline
** Also says the significant amount of debt in co's balance sheet could limit more strategic uses of capital
** Two of three brokerages rate the stock "buy", and one "hold"; with a median PT of $15
** Up to last close, stock has gained 112% YTD
(Reporting by Neil J Kanatt in Bengaluru)
((Neil.JKanatt@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。